Immunoassay for C-reactive protein
AssigneeOrtho-Clinical Diagnostics, Inc.
InventorsEdward R. Scalice, John L. Daiss
Life of this patent
Estimating the term…
Abstract
The present invention relates to new CRP immunoassay compositions. The compositions include a low affinity anti-human CRP monoclonal antibody, and an antiidiotypic antibody raised against it. The invention further provides a method for obtaining antiidiotypic monoclonal antibody populations directed to an antibody that is specific for a high concentration, high molecular weight target antigen.
Claims10
A method for performing a competitive immunoassay for detecting C-reactive protein comprising:
- i. contacting a sample with an immobilized a low affinity anti-human C-reactive protein antibody and a labeled antiidiotypic antibody,
- ii. detecting the label, and
- iii. correlating the detection of the label with the amount of C-reactive protein in the sample.
A method for performing a competitive immunoassay for detecting c-reactive protein comprising:
- i. contacting a sample with an immobilized antiidiotypic antibody and a labeled low affinity anti-human C-reactive protein antibody,
- ii. detecting the label, and
- iii. correlating the detection of the label with the amount of C-reactive protein in the sample.
The method of claim 8 wherein the low affinity antihuman C-reactive protein antibody is CRP5-23.
The method of claim 9 wherein the antiidiotypic antibody is antibody is capable of binding CRP5-23.
A kit for a competitive immunoassay comprising:
- a first antibody wherein said first antibody is a low affinity anti-human C-reactive protein antibody and a second antibody where said second antibody is an antiidiotypic antibody capable of binding said first antibody.
A hybridoma cell line, identified as CRP5-23, capable of producing a low affinity anti-human C-reactive protein antibody.
An antiidiotypic antibody raised against a low affinity anti-human C-reactive protein antibody.
A hybridoma cell line, identified as C23id2-6.3, capable of producing an antiidiotypic antibody.
Dependencies are inferred from the claim text.